Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Peregrine Says Lung Cancer Trial Data Erroneous - Quick Facts

RELATED NEWS
Trade PPHM now with 

Peregrine Pharmaceuticals Inc. (PPHM: Quote) announced that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments.

The company stated that due to the double-blind nature of the trial, it was not permitted to have access to either patient group assignments or related product coding information.

As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.

Click here to receive FREE breaking news email alerts for Peregrine Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks moved sharply higher over the course of the trading day on Tuesday, extending the recovery from the sell-off seen in recent weeks. The Nasdaq and the S&P 500 closed higher for the fourth consecutive session but remain well off their mid-September highs. Despite indications that the spread of Ebola inside the U.S. has been contained, the results of a new Gallup poll show the deadly disease had made its debut on a list of the top 10 most important problems facing the country. In another hotly contested Senate race, the results of a new Suffolk University/Boston Herald poll show incumbent Sen. Jeanne Shaheen, D-N.H., clinging to a narrow lead over Republican challenger Scott Brown.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.